# Asfar S Azmi

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 158 papers | 10,947 citations | 46984 47 h-index | 32815 100 g-index |
| 166 all docs | 166 docs citations | 166 times ranked | 17859 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review. Cancer and Metastasis Reviews, 2013, 32, 623-642. | 2.7 | 948 |
| 2 | Broad targeting of resistance to apoptosis in cancer. Seminars in Cancer Biology, 2015, 35, S78-S103. | 4.3 | 535 |
| 3 | Sustained proliferation in cancer: Mechanisms and novel therapeutic targets. Seminars in Cancer Biology, 2015, 35, S25-S54. | 4.3 | 468 |
| 4 | Broad targeting of angiogenesis for cancer prevention and therapy. Seminars in Cancer Biology, 2015, 35, S224-S243. | 4.3 | 375 |
| 5 | Evolving role of uPA/uPAR system in human cancers. Cancer Treatment Reviews, 2008, 34, 122-136. | 3.4 | 371 |
| 6 | Metformin Inhibits Cell Proliferation, Migration and Invasion by Attenuating CSC Function Mediated by Deregulating miRNAs in Pancreatic Cancer Cells. Cancer Prevention Research, 2012, 5, 355-364. | 0.7 | 317 |
| 7 | Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resistance Updates, 2010, 13, 109-118. | 6.5 | 313 |
| 8 | Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer and Metastasis Reviews, 2020, 39, 1179-1203. | 2.7 | 311 |
| 9 | Pancreatic cancer: understanding and overcoming chemoresistance. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 27-33. | 8.2 | 303 |
| 10 | Curcumin Analogue CDF Inhibits Pancreatic Tumor Growth by Switching on Suppressor microRNAs and Attenuating EZH2 Expression. Cancer Research, 2012, 72, 335-345. | 0.4 | 285 |
| 11 | Cancer prevention and therapy through the modulation of the tumor microenvironment. Seminars in Cancer Biology, 2015, 35, S199-S223. | 4.3 | 285 |
| 12 | Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars in Cancer Biology, 2015, 35, S5-S24. | 4.3 | 231 |
| 13 | Oxidative breakage of cellular DNA by plant polyphenols: A putative mechanism for anticancer properties. Seminars in Cancer Biology, 2007, 17, 370-376. | 4.3 | 221 |
| 14 | Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304. | 4.3 | 220 |
| 15 | Overview of Cancer Stem Cells (CSCs) and Mechanisms of Their Regulation: Implications for Cancer Therapy. Current Protocols in Pharmacology, 2013, 61, Unit 14.25. | 4.0 | 210 |
| 16 | Overâ€•expression of FoxM1 leads to epithelialâ€“mesenchymal transition and cancer stem cell phenotype in pancreatic cancer cells. Journal of Cellular Biochemistry, 2011, 112, 2296-2306. | 1.2 | 199 |
| 17 | Review on Molecular and Therapeutic Potential of Thymoquinone in Cancer. Nutrition and Cancer, 2010, 62, 938-946. | 0.9 | 198 |
| 18 | A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth <i>In Vitro</i> and <i>In Vivo</i>. Molecular Cancer Therapeutics, 2014, 13, 565-575. | 1.9 | 166 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 258-267. | 3.3 | 163 |
| 20 | Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment. PLoS ONE, 2012, 7, e50165. | 1.1 | 152 |
| 21 | KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. Cancer Treatment Reviews, 2020, 84, 101974. | 3.4 | 143 |
| 22 | Hypoxia Induced Aggressiveness of Prostate Cancer Cells Is Linked with Deregulated Expression of VEGF, IL-6 and miRNAs That Are Attenuated by CDF. PLoS ONE, 2012, 7, e43726. | 1.1 | 116 |
| 23 | The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 272-296. | 3.3 | 116 |
| 24 | The nuclear export protein XPO1 â€" from biology to targeted therapy. Nature Reviews Clinical Oncology, 2021, 18, 152-169. | 12.5 | 114 |
| 25 | Nonâ€peptidic small molecule inhibitors against Bclâ€2 for cancer therapy. Journal of Cellular Physiology, 2009, 218, 13-21. | 2.0 | 109 |
| 26 | Selective Inhibitors of Nuclear Export Block Pancreatic Cancer Cell Proliferation and Reduce Tumor Growth in Mice. Gastroenterology, 2013, 144, 447-456. | 0.6 | 109 |
| 27 | Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations. Molecular Cancer Therapeutics, 2010, 9, 3137-3144. | 1.9 | 104 |
| 28 | Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 122-130. | 3.3 | 99 |
| 29 | Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Seminars in Cancer Biology, 2015, 35, S55-S77. | 4.3 | 95 |
| 30 | A multi-targeted approach to suppress tumor-promoting inflammation. Seminars in Cancer Biology, 2015, 35, S151-S184. | 4.3 | 95 |
| 31 | Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opinion on Emerging Drugs, 2011, 16, 59-70. | 1.0 | 92 |
| 32 | Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-ÎºB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget, 2016, 7, 78883-78895. | 0.8 | 92 |
| 33 | Downâ€regulation of Notchâ€1 is associated with Akt and FoxM1 in inducing cell growth inhibition and apoptosis in prostate cancer cells. Journal of Cellular Biochemistry, 2011, 112, 78-88. | 1.2 | 81 |
| 34 | Structure-Activity Studies on Therapeutic Potential of Thymoquinone Analogs in Pancreatic Cancer. Pharmaceutical Research, 2010, 27, 1146-1158. | 1.7 | 77 |
| 35 | Paclitaxel and di-fluorinated curcumin loaded in albumin nanoparticles for targeted synergistic combination therapy of ovarian and cervical cancers. Colloids and Surfaces B: Biointerfaces, 2018, 167, 8-19. | 2.5 | 75 |
| 36 | An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Molecular Cancer, 2009, 8, 115. | 7.9 | 71 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Snail nuclear transport: The gateways regulating epithelial-to-mesenchymal transition?. Seminars in Cancer Biology, 2014, 27, 39-45. | 4.3 | 70 |
| 38 | Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2017, 16, 76-87. | 1.9 | 69 |
| 39 | Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy. Anticancer Research, 2011, 31, 1105-13. | 0.5 | 66 |
| 40 | MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. European Journal of Cancer, 2010, 46, 1122-1131. | 1.3 | 65 |
| 41 | Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas. Haematologica, 2013, 98, 1098-1106. | 1.7 | 59 |
| 42 | Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer, 2021, 20, 82. | 7.9 | 58 |
| 43 | Resveratrolâ€induced apoptosis is enhanced in low pH environments associated with cancer. Journal of Cellular Physiology, 2012, 227, 1493-1500. | 2.0 | 57 |
| 44 | <scp>microRNA</scp>â€based diagnostic and therapeutic applications in cancer medicine. Wiley Interdisciplinary Reviews RNA, 2021, 12, e1662. | 3.2 | 55 |
| 45 | FoxM1 is a Novel Target of a Natural Agent in Pancreatic Cancer. Pharmaceutical Research, 2010, 27, 1159-1168. | 1.7 | 54 |
| 46 | Pancreatic Cancer Stem-like Cells Display Aggressive Behavior Mediated via Activation of FoxQ1. Journal of Biological Chemistry, 2014, 289, 14520-14533. | 1.6 | 53 |
| 47 | Cellular DNA breakage by soy isoflavone genistein and its methylated structural analogue biochanin A. Molecular Nutrition and Food Research, 2009, 53, 1376-1385. | 1.5 | 52 |
| 48 | Targeting CSCs in Tumor Microenvironment: The Potential Role of ROS-Associated miRNAs in Tumor Aggressiveness. Current Stem Cell Research and Therapy, 2013, 9, 22-35. | 0.6 | 50 |
| 49 | Progress in Nanotechnology Based Approaches to Enhance the Potential of Chemopreventive Agents. Cancers, 2011, 3, 428-445. | 1.7 | 48 |
| 50 | Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers. Annals of Translational Medicine, 2014, 2, 59. | 0.7 | 48 |
| 51 | Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer. Oncotarget, 2014, 5, 3444-3454. | 0.8 | 47 |
| 52 | miRNA and Gene Expression in Pancreatic Ductal Adenocarcinoma. American Journal of Pathology, 2019, 189, 58-70. | 1.9 | 46 |
| 53 | Targeting CSC-Related miRNAs for Cancer Therapy by Natural Agents. Current Drug Targets, 2012, 13, 1858-1868. | 1.0 | 45 |
| 54 | Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumors. Oncotarget, 2011, 2, 378-392. | 0.8 | 45 |

| # | Article | IF | Citations |
| --- | --- | --- | --- |
| 55 | Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis, 2009, 24, 413-418. | 1.0 | 44 |
| 56 | Ras and exosome signaling. Seminars in Cancer Biology, 2019, 54, 131-137. | 4.3 | 44 |
| 57 | Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget, 2017, 8, 82144-82155. | 0.8 | 43 |
| 58 | Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-Î°B Signaling Pathways. PLoS ONE, 2011, 6, e20537. | 1.1 | 43 |
| 59 | Network pharmacology for cancer drug discovery: are we there yet?. Future Medicinal Chemistry, 2012, 4, 939-941. | 1.1 | 42 |
| 60 | Exportin 1 inhibition as antiviral therapy. Drug Discovery Today, 2020, 25, 1775-1781. | 3.2 | 41 |
| 61 | Targeting KRAS in pancreatic cancer: new drugs on the horizon. Cancer and Metastasis Reviews, 2021, 40, 819-835. | 2.7 | 41 |
| 62 | Class I and Class II Histone Deacetylases Are Potential Therapeutic Targets for Treating Pancreatic Cancer. PLoS ONE, 2012, 7, e52095. | 1.1 | 41 |
| 63 | Plant polyphenols mobilize nuclear copper in human peripheral lymphocytes leading to oxidatively generated DNA breakage: Implications for an anticancer mechanism. Free Radical Research, 2008, 42, 764-772. | 1.5 | 40 |
| 64 | Old Wine in a New Bottle: The Warburg Effect and Anticancer Mechanisms of Resveratrol. Current Pharmaceutical Design, 2012, 18, 1645-1654. | 0.9 | 40 |
| 65 | Targeting CSCs within the tumor microenvironment for cancer therapy: a potential role of mesenchymal stem cells. Expert Opinion on Therapeutic Targets, 2012, 16, 1041-1054. | 1.5 | 40 |
| 66 | Activated Kâ€Ras and INK4a/Arf deficiency promote aggressiveness of pancreatic cancer by induction of EMT consistent with cancer stem cell phenotype. Journal of Cellular Physiology, 2013, 228, 556-562. | 2.0 | 40 |
| 67 | Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention. Current Drug Targets, 2013, 14, 1094-1100. | 1.0 | 40 |
| 68 | Gastrointestinal stromal tumor: a review of current and emerging therapies. Cancer and Metastasis Reviews, 2021, 40, 625-641. | 2.7 | 39 |
| 69 | The anthocyanidin delphinidin mobilizes endogenous copper ions from human lymphocytes leading to oxidative degradation of cellular DNA. Toxicology, 2008, 249, 19-25. | 2.0 | 37 |
| 70 | Reactivation of p53 by Novel MDM2 Inhibitors: Implications for Pancreatic Cancer Therapy. Current Cancer Drug Targets, 2010, 10, 319-331. | 0.8 | 37 |
| 71 | KRAS Inhibitorsâ€" yes but what next? Direct targeting of KRASâ€" vaccines, adoptive T cell therapy and beyond. Cancer Treatment Reviews, 2021, 101, 102309. | 3.4 | 37 |
| 72 | The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Review of Anticancer Therapy, 2018, 18, 131-148. | 1.1 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. Cancers, 2011, 3, 1527-1549. | 1.7 | 31 |
| 74 | Differentially Expressed miRNAs in Cancer-Stem-Like Cells: Markers for Tumor Cell Aggressiveness of Pancreatic Cancer. Stem Cells and Development, 2014, 23, 1947-1958. | 1.1 | 31 |
| 75 | F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities. Seminars in Cancer Biology, 2016, 36, 95-104. | 4.3 | 29 |
| 76 | Targeting Nuclear Exporter Protein XPO1/CRM1 in Gastric Cancer. International Journal of Molecular Sciences, 2019, 20, 4826. | 1.8 | 29 |
| 77 | Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer. Oncotarget, 2017, 8, 44295-44311. | 0.8 | 29 |
| 78 | Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Scientific Reports, 2015, 5, 16077. | 1.6 | 28 |
| 79 | Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone. Cancer Letters, 2016, 383, 309-317. | 3.2 | 28 |
| 80 | Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancerâ€"A review. Critical Reviews in Oncology/Hematology, 2020, 145, 102841. | 2.0 | 28 |
| 81 | Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2020, 26, 1338-1348. | 3.2 | 28 |
| 82 | The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. Journal of Clinical Medicine, 2016, 5, 59. | 1.0 | 27 |
| 83 | Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth. Cancers, 2020, 12, 750. | 1.7 | 27 |
| 84 | Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation. Small GTPases, 2019, 10, 367-377. | 0.7 | 26 |
| 85 | Network insights on oxaliplatin antiâ€cancer mechanisms. Clinical and Translational Medicine, 2012, 1, 26. | 1.7 | 25 |
| 86 | Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. OncoTargets and Therapy, 2014, 7, 187. | 1.0 | 25 |
| 87 | Adopting Network Pharmacology for Cancer Drug Discovery. Current Drug Discovery Technologies, 2013, 10, 95-105. | 0.6 | 25 |
| 88 | Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition. Current Cancer Drug Targets, 2013, 13, 906-914. | 0.8 | 24 |
| 89 | Gastric Cancer Heterogeneity and Clinical Outcomes. Technology in Cancer Research and Treatment, 2020, 19, 153303382093547. | 0.8 | 24 |
| 90 | Prior exposure to restraint stress enhances 7,12-dimethylbenz(a)anthracene (DMBA) induced DNA damage in rats. FEBS Letters, 2006, 580, 3995-3999. | 1.3 | 23 |

| # | Article | IF | Citations |
| --- | --- | --- | --- |
| 91 | The immunological contribution of NF-ÎºB within the tumor microenvironment: A potential protective role of zinc as an anti-tumor agent. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 160-172. | 3.3 | 23 |
| 92 | Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. International Journal of Molecular Sciences, 2020, 21, 237. | 1.8 | 23 |
| 93 | PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers, 2019, 11, 1902. | 1.7 | 22 |
| 94 | Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges. Expert Opinion on Pharmacotherapy, 2019, 20, 535-546. | 0.9 | 22 |
| 95 | Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective. Epigenomics, 2011, 3, 747-759. | 1.0 | 19 |
| 96 | Targeting Cancer at the Nuclear Pore. Journal of Clinical Oncology, 2016, 34, 4180-4182. | 0.8 | 18 |
| 97 | Natural agents inhibit colon cancer cell proliferation and alter microbial diversity in mice. PLoS ONE, 2020, 15, e0229823. | 1.1 | 18 |
| 98 | Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside. Cancers, 2021, 13, 2777. | 1.7 | 18 |
| 99 | PAR-4 as a possible new target for pancreatic cancer therapy. Expert Opinion on Therapeutic Targets, 2010, 14, 611-620. | 1.5 | 17 |
| 100 | Rectifying cancer drug discovery through network pharmacology. Future Medicinal Chemistry, 2014, 6, 529-539. | 1.1 | 17 |
| 101 | Nuclear Export Inhibition for Pancreatic Cancer Therapy. Cancers, 2018, 10, 138. | 1.7 | 17 |
| 102 | Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study. Clinical Cancer Research, 2021, 27, 3307-3316. | 3.2 | 17 |
| 103 | Pro-oxidant activity of dietary chemopreventive agents: an under-appreciated anti-cancer property. F1000Research, 2013, 2, 135. | 0.8 | 17 |
| 104 | Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling. Current Pharmaceutical Design, 2014, 20, 56-65. | 0.9 | 17 |
| 105 | Systems analysis reveals a transcriptional reversal of the mesenchymal phenotype induced by SNAIL-inhibitor GN-25. BMC Systems Biology, 2013, 7, 85. | 3.0 | 16 |
| 106 | Circular RNAs in acute myeloid leukemia. Molecular Cancer, 2021, 20, 149. | 7.9 | 16 |
| 107 | Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells. Heliyon, 2020, 6, e05442. | 1.4 | 15 |
| 108 | Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanism. American Journal of Translational Research (discontinued), 2011, 3, 374-82. | 0.0 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Molecular Cancer Therapeutics, 2021, 20, 1836-1845. | 1.9 | 14 |
| 110 | Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs. Cancers, 2021, 13, 4161. | 1.7 | 14 |
| 111 | Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opinion on Therapeutic Targets, 2018, 22, 9-17. | 1.5 | 13 |
| 112 | Can network pharmacology rescue neutraceutical cancer research?. Drug Discovery Today, 2012, 17, 807-809. | 3.2 | 12 |
| 113 | Pan-Bcl-2 Inhibitor AT-101 Enhances Tumor Cell Killing by EGFR Targeted T Cells. PLoS ONE, 2012, 7, e47520. | 1.1 | 12 |
| 114 | Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12Câ€"Mutant Cancers. Cancer Research Communications, 2022, 2, 342-352. | 0.7 | 12 |
| 115 | The evolving role of nuclear transporters in cancer. Seminars in Cancer Biology, 2014, 27, 1-2. | 4.3 | 11 |
| 116 | Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression. Oncotarget, 2018, 9, 35327-35342. | 0.8 | 11 |
| 117 | Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms. Leukemia, 2022, 36, 601-612. | 3.3 | 11 |
| 118 | Prooxidant anticancer activity of plant-derived polyphenolic compounds: An underappreciated phenomenon. , 2020, , 221-236. | | 10 |
| 119 | Network Insights into the Genes Regulated by Hepatocyte Nuclear Factor 4 in Response to Drug Induced Perturbations: A Review. Current Drug Discovery Technologies, 2013, 10, 147-154. | 0.6 | 10 |
| 120 | Network Perspectives on HDM2 Inhibitor Chemotherapy Combinations. Current Pharmaceutical Design, 2011, 17, 640-652. | 0.9 | 9 |
| 121 | DNA-Methylation-Caused Downregulation of miR-30 Contributes to the High Expression of XPO1 and the Aggressive Growth of Tumors in Pancreatic Ductal Adenocarcinoma. Cancers, 2019, 11, 1101. | 1.7 | 9 |
| 122 | Connecting the Human Microbiome and Pancreatic Cancer. Cancer and Metastasis Reviews, 2022, 41, 317-331. | 2.7 | 9 |
| 123 | Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model. Heliyon, 2019, 5, e02290. | 1.4 | 8 |
| 124 | Systems Biology Approaches to Pancreatic Cancer Detection, Prevention and Treatment. Current Pharmaceutical Design, 2014, 20, 73-80. | 0.9 | 8 |
| 125 | PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma. Cancers, 2022, 14, 160. | 1.7 | 8 |
| 126 | KRASG12C inhibitors on the horizon. Future Medicinal Chemistry, 2019, 11, 923-925. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Restraint stress abates the antioxidant potential of melatonin on dimethyl benz (a) anthracene (DMBA) induced carcinogenesis. Medical Oncology, 2020, 37, 96. | 1.2 | 7 |
| 128 | Editorial (Hot Topic: Network Pharmacology: An Emerging Field in Cancer Drug Discovery). Current Drug Discovery Technologies, 2013, 10, 93-94. | 0.6 | 6 |
| 129 | Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. International Journal of Molecular Sciences, 2021, 22, 6676. | 1.8 | 5 |
| 130 | Prostate cancer stem cells: molecular characterization for targeted therapy. Asian Journal of Andrology, 2012, 14, 659-660. | 0.8 | 5 |
| 131 | Abstract 1358: p21 activated kinase 4 (pak4) as a novel therapeutic target for non-hodgkin's lymphoma. Cancer Research, 2017, 77, 1358-1358. | 0.4 | 5 |
| 132 | Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy. Journal of Stem Cell Research & Therapy, 2013, 01, . | 0.3 | 5 |
| 133 | MDM2 Inhibitors for Pancreatic Cancer Therapy. Mini-Reviews in Medicinal Chemistry, 2010, 10, 518-526. | 1.1 | 4 |
| 134 | Editorial [Hot Topic: Pharmaceutical Reactivation of p53 Pathways in Cancer (Executive Guest Editor:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf | 0.9 | 4 |
| 135 | Nuclear export mechanisms of circular RNAs: size does matter. Non-coding RNA Investigation, 2018, 2, 52-52. | 0.6 | 4 |
| 136 | Regulation of KRAS-PAK4 Axis by MicroRNAs in Cancer. Current Pharmaceutical Design, 2014, 20, 5275-5278. | 0.9 | 4 |
| 137 | p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?. Future Medicinal Chemistry, 2015, 7, 5-7. | 1.1 | 3 |
| 138 | Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC). Lung Cancer, 2021, 160, 92-98. | 0.9 | 3 |
| 139 | Attenuation of Multifocal Cell Survival Signaling by Bioactive Phytochemicals in the Prevention and Therapy of Cancer. Evidence-based Anticancer Complementary and Alternative Medicine, 2013, , 269-310. | 0.1 | 2 |
| 140 | Updates and new directions in the use of radiation therapy for the treatment of pancreatic adenocarcinoma: dose, sensitization, and novel technology. Cancer and Metastasis Reviews, 2021, 40, 879-889. | 2.7 | 2 |
| 141 | Clinical progress of KRAS-targeted therapies: what next?. Future Medicinal Chemistry, 0, , . | 1.1 | 2 |
| 142 | Editorial (Thematic Issue: Systems and Network Biology in Pharmaceutical Drug Discovery). Current Pharmaceutical Design, 2014, 20, 2-3. | 0.9 | 1 |
| 143 | Systems and Network Pharmacology Strategies for Pancreatic Ductal Adenocarcinoma Therapy. , 2014, , 405-425. | | 1 |
| 144 | Abstract 1058: Inhibition of nuclear transport protein XPO1 potentiates the effect of KRASG12Cinhibitors. , 2021, , . | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Abstract 1756: Preclinical activity in non-Hodgkin's lymphoma of Selinexor, a selective inhibitor of nuclear export (SINE), is enhanced through combination with standard-of-care therapies. , 2015, , . | | 1 |
| 146 | Abstract 4688: Overcoming drug resistance and stemness in oncogenic kras driven pancreatic ductal adenocarcinoma through PAK4 inhibition. , 2015, , . | | 1 |
| 147 | Abstract B38: Clinical translation of nuclear export inhibitor in metastatic pancreatic cancer. , 2016, , . | | 1 |
| 148 | Systems and Network Biology to Investigate Epigenetic De-regulatory Mechanisms of MicroRNAs in Pancreatic Cancer. , 2013, , 1-12. | | 0 |
| 149 | Providing activation-induced cytidine deaminase (AID) to nuclear export inhibitors. Response to: "Complex downstream effects of nuclear export inhibition in B-cell lymphomas: a possible role for activation-induced cytidine deaminase". Haematologica, 2013, 98, e123-e123. | 1.7 | 0 |
| 150 | Prioritizing Diagnostic, Prognostic, and Therapeutic MicroRNAs in Pancreatic Cancer. , 2014, , 345-363. | | 0 |
| 151 | The Biological Roles of MicroRNAs in Cancer Stem Cells. , 2014, , 295-320. | | 0 |
| 152 | Systems Biology of Pancreatic Cancer Stem Cells. , 2014, , 297-322. | | 0 |
| 153 | Opening a Pandora's (F)-box in cancer. Seminars in Cancer Biology, 2016, 36, 1-2. | 4.3 | 0 |
| 154 | Some chinks in RAS armor. Seminars in Cancer Biology, 2019, 54, iii-iv. | 4.3 | 0 |
| 155 | Network Pharmacology: An Emerging Area in Anti-Cancer Drug Discovery. , 2012, , 393-418. | | 0 |
| 156 | The Biology of the Deadly Love Connection Between Obesity, Diabetes, and Breast Cancer. , 2013, , 117-142. | | 0 |
| 157 | Systems Biology Approaches in the Design of Effective miRNA-Targeted Therapeutics. , 2014, , 327-337. | | 0 |
| 158 | Abstract 5315: Anti-tumor activity of KRASG12C inhibitors is enhanced when combined with Cdc42 effector p21-activated kinase 4 targeting agents. Cancer Research, 2022, 82, 5315-5315. | 0.4 | 0 |